RECOMBINANT INTERLEUKIN-2 TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL-CANCER - EFFECT ON NATURAL CYTOTOXICITY

被引：11

作者：

PARK, KGM ^{[1
]}

HEYS, SD ^{[1
]}

MURRAY, JB ^{[1
]}

HAYES, PD ^{[1
]}

ASHBY, JA ^{[1
]}

FRANKS, CR ^{[1
]}

EREMIN, O ^{[1
]}

机构：

[1] EUROCETUS BV,1105J AMSTERDAM,NETHERLANDS

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 1992年 / 35卷 / 01期

关键词：

INTERLEUKIN-2; COLORECTAL CANCER; NATURAL CYTOTOXICITY; CYTOTOXICITY;

D O I：

10.1007/BF01741055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1 +/- 6.9%, mean +/- SD; posttreatment: 39.2 +/- 6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

引用

页码：53 / 58

页数：6

共 50 条

[21] Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
Schmidt-Wolf, IGH
Finke, S
Trojaneck, B
Denkena, A
Lefterova, P
Schwella, N
Heuft, HG
Prange, G
Korte, M
Takeya, M
Dorbic, T
Neubauer, A
Wittig, B
Huhn, D
BRITISH JOURNAL OF CANCER, 1999, 81 (06) : 1009 - 1016
[22] Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer
Hiroaki Saito
Shunichi Tsujitani
Kuniyuki Katano
Masahide Ikeguchi
Michio Maeta
Nobuaki Kaibara
Surgery Today, 1998, 28 : 1115 - 1117
[23] THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA BY CONTINUOUS INTRAVENOUS-INFUSION OF RECOMBINANT INTERLEUKIN-2
GORE, ME
GALLIGIONI, E
KEEN, CW
SORIO, R
LORIAUX, EM
GROBBEN, HC
FRANKS, CR
EUROPEAN JOURNAL OF CANCER, 1994, 30A (03) : 329 - 333
[24] Interleukin-2 plus chemotherapy for patients with metastatic melanoma
Paciucci, PA
Ryder, JS
Mandeli, JP
Morris, JC
Holland, JF
MELANOMA RESEARCH, 2000, 10 (03) : 291 - 295
[25] Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells
Qi, Yuan-Ying
Lu, Chao
Ju, Ying
Wang, Zi-E
Li, Yuan-Tang
Shen, Ya-Juan
Lu, Zhi-Ming
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (18) : 7857 - 7861
[26] Subcutaneous interleukin-2 and interferon in the treatment of patients with metastatic renal cell carcinoma -: Less efficacy compared with intravenous interleukin-2 and interferon α
Ravaud, A
Delva, R
Gomez, F
Chevreau, C
Douillard, JY
Peny, J
Coudert, B
Négrier, S
CANCER, 2002, 95 (11) : 2324 - 2330
[27] Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2
Quan, Walter D. Y., Jr.
Walker, Paul R.
Quan, Francine M.
Ramirez, Maria
Elsamaloty, Haitham M.
Ghai, Vikas
Vinogradov, Mikhail
Liles, Darla K.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (05) : 437 - 442
[28] 2ND HEPATIC RESECTION FOR METASTATIC COLORECTAL-CANCER
ODWYER, PJ
ORIORDAIN, DS
MARTIN, EW
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1991, 17 (04): : 403 - 404
[29] IMMUNOPATHOLOGICAL CHANGES IN THE SKIN FOLLOWING RECOMBINANT INTERLEUKIN-2 TREATMENT
BLESSING, K
PARK, KGM
HEYS, SD
KING, G
EREMIN, O
JOURNAL OF PATHOLOGY, 1992, 167 (03): : 313 - 319
[30] Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer
J. Y. Douillard
J. Bennouna
F. Vavasseur
R. Deporte-Fety
P. Thomare
F. Giacalone
K. Meflah
Cancer Immunology, Immunotherapy, 2000, 49 : 56 - 61

← 1 2 3 4 5 →